Scienture (NASDAQ:SCNX) Announces Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Scienture (NASDAQ:SCNX) announced its quarterly earnings data on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.15, FiscalAI reports. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.40 million.

Scienture Stock Down 1.9%

Shares of NASDAQ SCNX traded down $0.01 during mid-day trading on Friday, reaching $0.40. 313,564 shares of the company were exchanged, compared to its average volume of 2,380,695. The stock has a market cap of $16.37 million, a price-to-earnings ratio of -0.15 and a beta of 3.32. Scienture has a 1 year low of $0.24 and a 1 year high of $2.60. The firm has a 50-day moving average of $0.40 and a 200 day moving average of $0.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Scienture stock. Virtu Financial LLC acquired a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture as of its most recent SEC filing. Institutional investors own 5.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SCNX shares. Maxim Group began coverage on Scienture in a research note on Tuesday, February 24th. They set a “buy” rating and a $1.50 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a research note on Friday, March 27th. Finally, Wall Street Zen upgraded shares of Scienture to a “hold” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $1.50.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.